Torkinib

SKU: orb1305518

Description

Torkinib

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 1092351-67-1
• MW: 308.34
• Purity: 99.23%
• Formula: C₁₆H₁₆N₆O
• SMILES: CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12
• Target: PI3K,Autophagy,mTOR,Apoptosis,Mitophagy
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.49 mM);DMSO:55 mg/mL (178.37 mM)

Bioactivity

• Target IC50:
  p110δ:0.10 μM (cell free)|mTORC2:58 nM (cell free)|Scr:1.4 μM|Abl:3.6 μM|DNA-PK:410 nM|p110α:2 μM|PDGFR:410 nM|Hck:1.2 μM|p110γ:1.3 μM|mTOR:8 nM (cell free)|mTORC1:30 nM (cell free)|p110β:2.2 μM|Scr (T338I):5.1 μM|EGFR:4.4 μM|EphB4:3.4 μM|VEGFR2:1.5 μM
• In Vivo:
  In mouse p190 model, short-term oral dosing with Torkinib in a dose-dependent manner significantly reduced leukemic burden in the spleen and bone marrow. In a long-term survival study, oral dosing of Torkinib (30 and 60 mg/kg) significantly delaye the onset of leukemia. In fat and liver, Torkinib was able to completely inhibi the phosphorylation of Akt at S473 and T308. Surprisingly, Torkinib was only partially able to inhibi the phosphorylation of Akt in skeletal musclee and was more effective at inhibitin the phosphorylation of T308 than S473, despite it's ability to fully inhibi the phosphorylation of 4EBP1 and S6.
• In Vitro:
  Torkinib (PP242) potently inhibited mTOR IC50 8 nM) but was much less active against Other PI3-K family members. Testing of this compound against 219 protein kinases revealed remarkable selectivity relative to the protein kinome. In BT549 cells, PP242 inhibite the phosphorylation of Akt the mTOR substratee p70S6K, and its downstream target S6. PP242 suppressed growth by > 90%, with low nanomolar potency (GI50: 12 nM). PP242 had greater anti Proliferative potency relative to rapamycin in a panel of solid tumor cell lines carrying either PI3K gain-of-function or PTEN loss-of-function.
• Cell Research:
  Cells were seeded in triplicate wells of 96-well flat bottom culture plates for 48 hr in the presence of increasing concentration of indicated inhibitors. Cell viability and median-effect dose affecting growth ( IC50 was determined usin the MTS assay. Absorbance Values (490 nM) were normalized to controls and expressed as %MTS conversion. Wells lacking cells but with MTS added was used a the zero value when normalizing. For drug combination experiments, a range of fixed ratios of inhibitors was used to assess synergy usin the combination index (CI) with CalcuSyn software according to the median-effect method as previously described. For proliferation experiments with PC-3, SKOV3, 786-O, and U87 cells the CellTiter-Glo Luminescent reagent was used followin the manufacturer's instructions. Quantitation was performed as mentioned above.
• Animal Research:
  Drugs were prepared in 100 μL of Vehicle containing 20% DMSO, 40% PEG-400, and 40% saline. Six-wk-old Male C57B-/- mice were fasted overnight prior to drug treatment. PP242 (0.4 mg), rapamycin (0.1 mg), or Vehicle alone was injected IP. After 30 min fo the rapamycin-treated mouse or 10 min fo the PP242 and Vehicle-treated mice, 250 mU of Insulin in 100 μL of saline was injected IP. 15 min afte the Insulin injection the mice were killed by CO2 asphyxiation followed by cervical dislocation. Tissues were Harvested and frozen on liquid nitrogen in 200 μL of cap lysis buffer the frozen tissue was thawed on ice, manually disrupted with a mortar and pestle, and then further processed with a micro tissue-homogenizer the protein concentration o the cleared lysate was measured by Bradford assay and 5–10 μg of protein was analyzed by Western blot as described above.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Apoptosis, Autophagy, Inhibitor, Mammalian target of Rapamycin, inhibit, mTOR, mTORC1, mTORC2, Mitophagy, Mitochondrial Autophagy, Torkinib, PP242, PP-242, PP 242, p110δ

Compound Identifiers

PubChem CID

135565635